While the mechanism of spread of<unk> -CoV is currently not known, based on experience with prior coronaviruses, such as SARS, the WHO currently recommends that all individuals coming into contact with<unk>  suspects should (in addition to standard precautions): * Wear a medical mask * Wear eye protection (i.e. goggles or a face shield) * Wear a clean, non sterile, long sleeved gown; and gloves (some procedures may require sterile gloves) * Perform hand hygiene before and after contact with the person and his or her surroundings and immediately after removal of personal protective equipment (PPE) For procedures which carry a risk of aerosolization, such as intubation, the WHO recommends that care providers also: * Wear a particulate respirator and, when putting on a disposable particulate respirator, always check the seal * Wear eye protection (i.e. goggles or a face shield) * Wear a clean, non-sterile, long-sleeved gown and gloves (some of these procedures require sterile gloves) * Wear an impermeable apron for some procedures with expected high fluid volumes that might penetrate the gown * Perform procedures in an adequately ventilated room; i.e. minimum of 6 to 12 air changes per hour in facilities with a mechanically ventilated room and at least 60 liters/second/patient in facilities with natural ventilation * Limit the number of persons present in the room to the absolute minimum required for the person's care and support * Perform hand hygiene before and after contact with the person and his or her surroundings and after PPE removal. The duration of infectivity is also unknown so it is unclear how long people must be isolated, but current recommendations are for 24 hours after resolution of symptoms. In the SARS outbreak the virus was not cultured from people after the resolution of their symptoms. It is believed that the existing SARS research may provide a useful template for developing vaccines and therapeutics against a<unk> -CoV infection. As of March 2020 there was one (DNA based)<unk>  vaccine which completed phase I clinical trials in humans, and three others in progress all of which are viral vectored vaccines, two adenoviral vectored (ChAdOx1-MERS, BVRS-GamVac) and one MVA vectored (MVA-MERS-S).
MERS
BHIE
BIRCH
NOMESCO
CAPOX
DRACO
MedChi
SCAPER